Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VICTOR-3 metronomic maintenance therapy in advanced or metastatic triple-negative breast cancer
2016-001864-12Phase 2Terminated
- Sponsor
- Mario Negri Institute for Pharmacological Research
- Start
- Nov 2017
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in triple-negative breast cancer (TNBC) comparing Metronomic Navelbine maintenance with Metronomic Navelbine + Capecitabine maintenance (2 arms). Primary endpoint: Proportion of patients alive and without progression after 12 weeks of maintenance therapy. Started Nov 2017; status: terminated.
02
Drugs
vinorelbinecapecitabine
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on 2016-001864-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-001864-12.